ArticleApplied microbiology and biotechnology2008
Efficient cloning system for construction of gene silencing vectors in Aspergillus niger.
Article in Applied microbiology and biotechnology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 50 citations in OpenAlex.
- A genetic tool to express long fungal biosynthetic genes.Fungal biology and biotechnology · 2023Article
- FungalBraid 2.0: expanding the synthetic biology toolbox for the biotechnological exploitation of filamentous fungi.Frontiers in bioengineering and biotechnology · 2023Article
- Genetic modification of asexual Epichloë endophytes with the perA gene for peramine biosynthesis.Molecular genetics and genomics : MGG · 2019Article
- Genetics, Molecular, and Proteomics Advances in Filamentous Fungi.Current microbiology · 2017Review
- Production of cyanophycin in Rhizopus oryzae through the expression of a cyanophycin synthetase encoding gene.Applied microbiology and biotechnology · 2012Article
- The Aspergillus niger multicopper oxidase family: analysis and overexpression of laccase-like encoding genes.Microbial cell factories · 2011Article
- Proteomic analysis of the secretory response of Aspergillus niger to D-maltose and D-xylose.PloS one · 2011Article
- Shotgun proteomics of Aspergillus niger microsomes upon D-xylose induction.Applied and environmental microbiology · 2010Article
- pHg/pSILBAγ vector system for efficient gene silencing in homobasidiomycetes: optimization of ihpRNA - triggering in the mycorrhizal fungus Laccaria bicolor.Microbial biotechnology · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
An approach based on Gateway recombination technology to efficiently construct silencing vectors was developed for use in the biotechnologically important fungus Aspergillus niger. The transcription activator of xylanolytic and cellulolytic genes XlnR of A. niger was chosen as target for gene silencing. Silencing was based on the expression vector pXLNRir that was constructed and used in co-transformation. From all the strains isolated (N = 77), nine showed poor xylan-degrading activities in two semi-quantitative plate assays testing different activities for xylan degradation. Upon induction on D-xylose, transcript levels of xlnR were decreased in the xlnR-silenced strains, compared to a wild-type background. Under these conditions, the transcript levels of xyrA and xynB (two genes regulated by XlnR) were also decreased for these xlnR-silenced strains. These results indicate that the newly developed system for rapid generation of silencing vectors is an effective tool for A. niger, and this can be used to generate strains with a tailored spectrum of enzyme activities or product formation by silencing specific genes encoding, e.g., regulators such as XlnR.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.